PAVmed

PAVmed, Inc. is a commercial-stage technology medical device company, which engages in the commercialization of medical technologies. It operates through the following divisions: Medical Devices, Diagnostics, Digital Health, and Emerging Innovations. Its products include cell collection devices, esophageal DNA tests, carpal tunnel release, implantable intraosseous vascular access devices, and antimicrobial resorbable ear tubes. The company was founded on June 26, 2014 and is headquartered in New York, NY.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

PAVmed, Inc. is a commercial-stage technology medical device company, which engages in the commercialization of medical technologies. It operates through the following divisions: Medical Devices, Diagnostics, Digital Health, and Emerging Innovations. The company's products include cell collection devices, esophageal DNA tests, carpal tunnel release, implantable intraosseous vascular access devices, and antimicrobial resorbable ear tubes. PAVmed was founded on June 26, 2014 and is headquartered in New York, NY.

The company tapped a respected figure in its industry as a board vice chairman.

Why PAVmed Soared by 12% on Wednesday

NEW YORK--(BUSINESS WIRE)---- $pavm--Stanley Lapidus, former Chairman & CEO of Exact Sciences, joins PAVmed subsidiary Lucid Diagnostics as Vice Chairman of its Board of Directors.

Stanley Lapidus, Founder and Former Chairman & CEO of Exact Sciences, Joins PAVmed Subsidiary Lucid Diagnostics as Vice Chairman of its Board of Directors

NEW YORK--(BUSINESS WIRE)---- $PAVM--PAVmed Subsidiary Lucid Diagnostics launches strategic partnership with direct-to-consumer telemedicine company UpScriptHealth.

PAVmed Subsidiary Lucid Diagnostics Launches Strategic Partnership with Direct-to-Consumer Telemedicine Company UpScriptHealth

PAVmed's main commercial-stage product, EsoCheck/EsoGuard, is a life-saving product addressing a $25bil market and is supported by Exact Sciences founder Stanley Lapidus.

PAVmed: A True Game-Changer For Medical Device Innovation

NEW YORK, June 14, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical technology company, today announced the appointment of prominent global technology industry leader Tim Baxter, to its Board of Directors. Mr. Baxter will serve as Chair of the Company's Nomination Committee and as a member of its Audit Committee.

Tim Baxter, Former CEO of Samsung Electronics North America and Global Technology Industry Leader, Joins PAVmed Board of Directors

NEW YORK, June 10, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announced that its major subsidiary, Lucid Diagnostics Inc. (“Lucid”), has completed European IVDD CE Mark certification of its EsoGuard® Esophageal DNA Test (“EsoGuard”).

PAVmed Subsidiary Lucid Diagnostics Completes European CE Mark Certification of its EsoGuard Esophageal DNA Test

New subsidiary Veris acquires privately held oncology digital health company Oncodisc Inc.

PAVmed Launches Digital Health Company Veris Health Inc.

NEW YORK, May 26, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, and its major subsidiary Lucid Diagnostics Inc. (“Lucid”), today announced that Lucid's EsoCheck® Esophageal Cell Collection Device with Collect+Protect™ technology (“EsoCheck”) has received CE Mark certification.

PAVmed Subsidiary Lucid Diagnostics Receives CE Mark Certification for its EsoCheck® Esophageal Cell Collection Device

NEW YORK, May 25, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announced that it has received CE Mark certification for its CarpX® minimally invasive carpal tunnel device.

PAVmed Receives European CE Mark Certification for its CarpX® Minimally Invasive Carpal Tunnel Device

Initial NYU experience in 99 patients demonstrated EsoCheck and EsoGuard capable of detecting esophageal precancer in chronic heartburn patients

Data Presented at Digestive Disease Week 2021 Support Clinical Utility of PAVmed Subsidiary Lucid Diagnostics' EsoCheck and EsoGuard Technologies

PAVmed Inc. (PAVM) CEO Lishan Aklog on Q1 2021 Results - Earnings Call Transcript

Conference call to be held today at 4 :30 P M E D T

PAVmed Provides Business Update and First Quarter 2021 Financial Results

Dr. David Poppers to present on his initial experience with Lucid's EsoCheck and EsoGuard

PAVmed Subsidiary Lucid Diagnostics Announces Upcoming Presentation at Digestive Disease Week 2021

Four new senior executives will support growth strategy focused on multi-channel EsoGuard commercialization

PAVmed Subsidiary Lucid Diagnostics Expands Commercial Leadership Team

Company conference call and webcast at 4:30 PM EDT

PAVmed to Hold Business Update Conference Call on May 17, 2021

NEW YORK, April 29, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), a highly differentiated, multi-product, commercial-stage medical technology company, today announced that its major subsidiary Lucid Diagnostics Inc. (“Lucid” or the “Company”) has appointed nationally recognized healthcare executive Jacque J. Sokolov to its Board of Directors (the “Board”). Dr. Sokolov will help establish and serve as the inaugural Chair of the Board's new Compliance & Quality Committee. He will also serve on Lucid's Audit and Compensation Committees.

Dr. Jacque Sokolov Joins PAVmed Subsidiary Lucid Diagnostics' Board of Directors

NEW YORK, April 27, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical technology company, today announced the appointment of prominent UK-based global industry executive, Debbie White, to its Board of Directors. Ms. White will serve on the Company's Audit and Compensation Committees.

Global Industry Executive Debbie White Joins PAVmed Board of Directors

Evogene

Savara

Synlogic

Analysts say these penny stocks are a buy right now & have bullish price targets to boot. The post Penny Stocks To Buy According To Analysts With Price Targets Up to 341% appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Penny Stocks To Buy According To Analysts With Price Targets Up to 341%

NEW YORK, April 15, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a commercial-stage, multi-product medical device company, today announced that Lishan Aklog, M.D., PAVmed's Chairman and Chief Executive Officer and Executive Chairman of its majority-owned subsidiary, Lucid Diagnostics Inc., was selected as one of the Top 50 Healthcare Technology CEOs of 2021 by Healthcare Technology Report.

PAVmed Chairman & CEO Lishan Aklog, M.D. named Top 50 Healthcare Technology CEO by Healthcare Technology Report

NEW YORK, April 08, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical technology company, today announced that Lishan Aklog, M.D., PAVmed's Chairman and Chief Executive Officer will present a corporate update at the 20th Annual Needham Healthcare Conference on April 15, 2021 at 8:00 AM EDT.

PAVmed to Present at the 20th Annual Needham Healthcare Conference

On-demand corporate presentation scheduled for March 17, 2021

PAVmed to Participate in M Vest LLC and Maxim Group LLC Inaugural Emerging Growth Virtual Conference

PAVmed has significant room to grow in the next year with their extensive pipeline for a range of clinical conditions, with an addressable market of over $3 billion. The company has recognizable and successful management led by Lishan Aklog, with the recent addition of Stanley Lapidus as a special advisor, the founder of Exact Sciences.

PAVmed Primed To Deliver Significant Value For Shareholders

NEW YORK, March 03, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announced that it has retired all of the Company's outstanding convertible debt, applying approximately $14.5 million of the proceeds of its recent underwritten common stock offering to pay the full outstanding balance of all of its convertible notes, which were held by Alto Opportunity Master Fund.

PAVmed Retires Convertible Debt

NEW YORK, March 01, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical technology company, today announced that the Advanced Medical Technology Association (AdvaMed), the world's leading medical technology trade association, has appointed Lishan Aklog, M.D., PAVmed's Chairman and Chief Executive Officer to its Board of Directors.

PAVmed Chairman and Chief Executive Officer Lishan Aklog, M.D., Elected to AdvaMed Board of Directors

NEW YORK, Feb. 25, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announced the closing of its previously announced underwritten public offering (the “Offering”) of approximately 9.8 million shares of its common stock for gross proceeds of approximately $45 million, before deducting underwriting discounts and commissions and other offering expenses payable by PAVmed.

News for PAVmed Stock (PAVM)